Lixivaptan, a vasopressin-2 receptor antagonist, is under development for the treatment of autosomal dominant polycystic kidney disease (ADPKD), an orphan disease with minimal treatment options. Tolvaptan, another vasopressin-2 receptor antagonist, is FDA approved to slow the progression of ADPKD but has produced liver safety signals. We prospectively compared the potential for lixivaptan versus tolvaptan to cause liver toxicity.
AASLD Liver Meeting, November 9-13, 2018, San Francisco, CA
By Lisl KM Shoda, Brett A. Howell, Jeffrey L Woodhead, Lorenzo Pelligrini, Scott Q. Siler